EUA — LLMpedia

EUA
Name	EUA
Type	Emergency regulatory measure
Established	2004
Jurisdiction	United States
Administered by	Food and Drug Administration
Purpose	Allow temporary use of unapproved medical products
Legislative basis	Food, Drug, and Cosmetic Act

Contents

EUA

An EUA is a regulatory mechanism that permits temporary access to medical products, vaccines, diagnostics, and therapeutics during declared public health emergencies. It balances expedited availability with Food and Drug Administration standards by authorizing products before full biologics license application or new drug application approval. EUAs have been invoked during infectious disease outbreaks and bioterrorism incidents, intersecting with statutes, public health declarations, and emergency policy from agencies such as the Department of Health and Human Services and the Centers for Disease Control and Prevention.

Definition and Overview

An EUA is issued under authorities granted by the Food, Drug, and Cosmetic Act and related emergency statutes, enabling the Food and Drug Administration to allow unapproved medical countermeasures for use against threats identified by the Secretary of Health and Human Services. The mechanism was shaped by events such as the 2001 anthrax attacks and formalized in amendments following recommendations from bodies including the Institute of Medicine and the National Academy of Medicine. EUAs specify the scope of use, conditions, and labeling and may be revoked or revised by the Commissioner of Food and Drugs.

The legal basis for EUA issuance is embedded in the Food, Drug, and Cosmetic Act as amended by instruments like the Project BioShield Act of 2004 and legislative provisions influenced by the Pandemic and All-Hazards Preparedness Act. The Secretary of Health and Human Services issues declarations under statutory criteria, and the Food and Drug Administration exercises regulatory review consistent with administrative law precedents such as decisions involving the D.C. Circuit Court of Appeals. Implementation requires coordination with the Department of Homeland Security, the Office of Management and Budget, and interagency entities like the Biomedical Advanced Research and Development Authority.

Before issuing an EUA, the Food and Drug Administration evaluates whether the agent at issue qualifies as a public health threat identified by the Secretary of Health and Human Services and whether there are no adequate, approved, and available alternatives. The assessment draws on data from clinical trials, animal rule studies, in vitro diagnostics, and real-world evidence compiled by institutions such as the National Institutes of Health, Centers for Disease Control and Prevention, and academic centers like Johns Hopkins University and Harvard Medical School. The FDA must determine that the known and potential benefits outweigh known and potential risks, considering input from advisory committees like the Vaccines and Related Biological Products Advisory Committee and scientific peer review from entities such as the National Academies.

EUAs have been used in responses to multiple crises. Prominent instances include authorization of anthrax countermeasures during the aftermath of the 2001 anthrax attacks, deployment of medical devices after the Hurricane Katrina response, and widespread authorizations during the COVID-19 pandemic. In the COVID-19 context, EUAs were granted for mRNA-1273 development by Moderna, Inc., the BNT162b2 product developed by Pfizer and BioNTech, point-of-care diagnostics from firms such as Abbott Laboratories, and therapeutics like remdesivir from Gilead Sciences. EUAs have also applied to emergency use of convalescent plasma and non-invasive ventilator technologies used in field settings coordinated with Federal Emergency Management Agency resources.

EUAs have sparked debate among stakeholders including patient advocacy groups, healthcare providers, legislators, and public health experts. Critics have raised concerns about perceived trade-offs between speed and evidentiary certainty, citing tensions evident during deliberations involving the Advisory Committee on Immunization Practices, media scrutiny from outlets such as The New York Times and The Washington Post, and inquiries in hearings before the United States Senate and the United States House of Representatives. Legal challenges have been mounted in federal courts contesting scope and conditions of authorizations, invoking claims grounded in administrative procedure precedents like Chevron U.S.A., Inc. v. Natural Resources Defense Council, Inc. and debates over federalism involving state public health authorities, exemplified by litigation referencing the Supreme Court of the United States. Public uptake and vaccine confidence have been influenced by communication from leaders including Anthony Fauci and agencies like the Centers for Disease Control and Prevention, alongside misinformation circulated on platforms such as Twitter and Facebook.

Other jurisdictions maintain analogous emergency pathways. The European Medicines Agency administers accelerated procedures like conditional marketing authorizations and emergency use through mechanisms coordinated with the European Commission and national regulators such as the Medicines and Healthcare products Regulatory Agency. Countries including Canada, Australia, and Japan have emergency access frameworks managed by agencies like Health Canada, the Therapeutic Goods Administration, and the Pharmaceuticals and Medical Devices Agency. International coordination occurs via forums including the World Health Organization and multilateral initiatives like the Global Health Security Agenda, which shape comparative regulatory practice and mutual recognition agreements among entities such as the International Coalition of Medicines Regulatory Authorities.